Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Elderly Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs Letrozole (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Paclitaxel
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms TOUCH
- 04 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jan 2019.
- 18 Dec 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
- 18 Dec 2018 Status changed from not yet recruiting to recruiting.